FibroBiologics Files Patent Application for a Cell-based Therapeutic for the Treatment Of Splenomegaly
FibroBiologics (Nasdaq: FBLG) has filed a patent application for treating splenomegaly using cell-based therapeutics. The application focuses on treating enlarged spleen conditions, which commonly occur in autoimmune disorders, chronic infections, and as a side effect of chemotherapy. The company's approach utilizes fibroblast-based therapies to address immune dysregulation, potentially offering a new treatment method for managing immune system overload and spleen enlargement. This development adds to FibroBiologics' portfolio of 160+ issued and pending patents in chronic disease therapeutics.
FibroBiologics (Nasdaq: FBLG) ha presentato una domanda di brevetto per il trattamento della splenomegalia utilizzando terapie basate su cellule. La domanda si concentra sul trattamento delle condizioni di ingrossamento della milza, che si verificano comunemente in disturbi autoimmuni, infezioni croniche e come effetto collaterale della chemioterapia. L'approccio dell'azienda utilizza terapie basate su fibroblasti per affrontare la disregolazione immunitaria, offrendo potenzialmente un nuovo metodo di trattamento per gestire il sovraccarico del sistema immunitario e l'ingrossamento della milza. Questo sviluppo si aggiunge al portafoglio di FibroBiologics, che conta oltre 160 brevetti concessi e in attesa per terapie delle malattie croniche.
FibroBiologics (Nasdaq: FBLG) ha presentado una solicitud de patente para el tratamiento de esplenomegalia utilizando terapias basadas en células. La solicitud se centra en el tratamiento de condiciones de aumento del bazo, que ocurren comúnmente en trastornos autoinmunes, infecciones crónicas y como efecto secundario de la quimioterapia. El enfoque de la empresa utiliza terapias basadas en fibroblastos para abordar la disregulación inmunitaria, ofreciendo potencialmente un nuevo método de tratamiento para gestionar la sobrecarga del sistema inmunológico y el aumento del bazo. Este desarrollo se suma al portafolio de FibroBiologics, que cuenta con más de 160 patentes emitidas y pendientes en terapias para enfermedades crónicas.
FibroBiologics (Nasdaq: FBLG)는 세포 기반 치료법을 사용하여 비장 비대를 치료하기 위한 특허 출원을 했습니다. 이 출원은 자가면역 질환, 만성 감염 및 항암 화학요법의 부작용으로 일반적으로 발생하는 비장 비대 상태의 치료에 초점을 맞추고 있습니다. 회사의 접근 방식은 면역 불균형을 해결하기 위해 섬유아세포 기반 요법을 활용하여 면역 시스템의 과부하 및 비장 비대를 관리하는 새로운 치료 방법을 제공할 수 있습니다. 이 개발은 FibroBiologics가 만성 질환 치료를 위해 보유한 160개 이상의 발급 및 대기 중인 특허 포트폴리오에 추가됩니다.
FibroBiologics (Nasdaq: FBLG) a déposé une demande de brevet pour traiter la splénomégalie en utilisant des thérapies basées sur des cellules. La demande se concentre sur le traitement des conditions d'élargissement de la rate, qui se produisent couramment dans les troubles auto-immuns, les infections chroniques et comme effet secondaire de la chimiothérapie. L'approche de l'entreprise utilise des thérapies basées sur des fibroblastes pour traiter la dysrégulation immunitaire, offrant potentiellement une nouvelle méthode de traitement pour gérer la surcharge du système immunitaire et l'élargissement de la rate. Ce développement s'ajoute au portefeuille de FibroBiologics, qui compte plus de 160 brevets délivrés et en attente dans le domaine des thérapies des maladies chroniques.
FibroBiologics (Nasdaq: FBLG) hat einen Patentantrag zur Behandlung von Splenomegalie mittels zellbasierter Therapeutika eingereicht. Der Antrag konzentriert sich auf die Behandlung von vergrößerten Milzbedingungen, die häufig bei Autoimmunerkrankungen, chronischen Infektionen und als Nebenwirkung von Chemotherapie auftreten. Der Ansatz des Unternehmens nutzt fibroblast-basierte Therapien zur Bekämpfung von Immun-Dysregulation und könnte eine neue Behandlungsmethode zur Bewältigung der Überlastung des Immunsystems und der Milzvergrößerung bieten. Diese Entwicklung ergänzt das Portfolio von FibroBiologics, das mehr als 160 erteilte und anhängige Patente im Bereich der chronischen Krankheiten umfasst.
- Filed new patent application expanding intellectual property portfolio
- Potential therapeutic application in multiple medical conditions (autoimmune disorders, chronic infections, chemotherapy side effects)
- Adds to existing portfolio of 160+ patents issued and pending
- None.
Insights
The patent application for splenomegaly treatment represents an innovative approach in addressing a significant unmet medical need. Splenomegaly affects patients across multiple disease states, including those with autoimmune conditions and cancer, creating a substantial market opportunity. However, this is still in the early patent stage without clinical validation.
The technology leverages FibroBiologics' extensive patent portfolio (160+ patents) and expertise in fibroblast-based therapeutics. The potential therapeutic could address a global splenomegaly market projected to reach
The company's approach of using fibroblasts for immune regulation could provide competitive advantages over current treatments, which are often to addressing underlying conditions or surgical intervention. However, success in patent prosecution and clinical development remains uncertain at this early stage.
HOUSTON, Nov. 19, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) , a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the filing of a patent application covering methods for treatment of splenomegaly using a cell-based therapeutic approach.
Splenomegaly, or an enlarged spleen, often occurs in connection with immune-related conditions and is seen in a variety of diseases, including autoimmune disorders and chronic infections. Additionally, it can also be caused by multiple rounds of chemotherapy, and depression treatment drugs. The spleen is essential for filtering blood, supporting immune function, and managing red blood cells. However, in cases of immune disorders, it can become overactive, leading to enlargement. Conditions like psoriasis, lupus, HIV, tuberculosis, and blood cancers such as lymphoma and leukemia are common causes of this issue. When the spleen enlarges to handle excess immune cells and inflammation, it can lead to discomfort, anemia, and a weakened immune system, increasing vulnerability to further infections.
“This patent application highlights the potential of fibroblast-based therapies to address immune-related disorders, such as splenomegaly,” said Pete O’Heeron, Founder & Chief Executive Officer of FibroBiologics. “Our technology leverages the unique capabilities of fibroblasts to target immune dysregulation, underscoring their promise in treating complex conditions linked to immune system dysfunction.”
“Filing this patent application marks an important milestone in developing fibroblast-based treatments for immune-driven diseases,” added Hamid Khoja, Ph.D., Chief Scientific Officer of FibroBiologics. “Unlike traditional treatments, fibroblasts may offer a potential solution aligned with the host biological processes to help regulate immune activity within the spleen, opening new possibilities for managing conditions that involve immune system overload and splenomegaly.”
For more information, please visit FibroBiologics’ website or email FibroBiologics at: info@fibrobiologics.com.
Cautionary Statement Regarding Forward-Looking Statements
This communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning the potential of fibroblast-based therapies to address immune-related disorders, such as splenomegaly and to open new possibilities for managing conditions that involve immune system overload and splenomegaly, and the promise of fibroblast-based therapies in treating complex conditions linked to immune system dysfunction. These forward-looking statements are based on FibroBiologics' management's current expectations, estimates, projections and beliefs, as well as a number of assumptions concerning future events. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics' management's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption "Risk Factors" and elsewhere in FibroBiologics' annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC's website, www.sec.gov. These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics' liquidity and its ability to maintain capital resources sufficient to conduct its business; (b) expectations regarding the initiation, progress and expected results of our R&D efforts and preclinical studies; (c) the unpredictable relationship between R&D and preclinical results and clinical study results; and (d) the ability of FibroBiologics to successfully prosecute its patent applications. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update, or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations.
About FibroBiologics
Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 160+ US and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy. For more information, visit www.FibroBiologics.com.
General Inquiries:
info@fibrobiologics.com
Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com
Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com
FAQ
What is the new patent application filed by FibroBiologics (FBLG) in November 2024?
What conditions can FibroBiologics' (FBLG) new splenomegaly treatment potentially address?
How many patents does FibroBiologics (FBLG) currently have in its portfolio?
